Theratechnologies Announces Completion of Acquisition by Future Pak. Click here to learn more.

Sign up for Email Alerts

Theratechnologies Announces Completion of Acquisition by Future Pak. Click here to learn more.

Youtube
X-twitter
Linkedin-in

HIV Scientific Papers

Long-term efficacy, safety and durability of ibalizumab in expanded access study.

2019

Author

Moyle G, Perno CF, Emu B, et al.

Volume

Poster #PE13/16 presented at: 17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland.

Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311) [abstract].

2019

Journal

Open Forum Infect Dis.

Author

Emu B, DeJesus E, Berhe M, et al.

Volume

6 (suppl 2):S303. Proceedings of IDWeek, 2019.

Learn More

Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311).

2019

Author

Emu B, DeJesus E, Berhe M, et al.

Volume

Poster #661 presented at: IDWeek; October 2-6, 2019; Washington, DC, USA.

Ibalizumab: 96-week data and efficacy in patients resistant to common antiretrovirals [abstract].

2019

Journal

Top Antivir Med.

Author

Emu B, DeJesus E, Berhe M, et al.

Volume

“27(suppl 1):179s. Proceedings of the 2019 Conference on Retroviruses and Opportunistic Infections. “

Learn More

Ibalizumab: 96-week data and efficacy in patients resistant to common antiretrovirals.

2019

Author

Emu B, Lalezari J, Kumar P, et al.

Volume

Poster #485 presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, Washington, USA.

Search

Theratechnologies